Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914309 | 0.81 | LMNA (0.35) | LMNAKMT2ANPC1RAB9AHTR5A | |
| SCHEMBL5723115 | 0.80 | KDM4E (0.46) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23304994 | 0.80 | SIGMAR1 (0.39) | LMNAKMT2ANPC1RAB9AHTR5A | |
| SCHEMBL2378171 | 0.79 | LMNA (0.60) | LMNAKMT2ANPC1RAB9A | |
| SCHEMBL5723473 | 0.79 | KDM4E (0.47) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL19511131 | 0.77 | FFAR4 (0.36) | HTR1A | |
| SCHEMBL11104349 | 0.76 | ALDH1A1 (0.39) | KMT2ANPC1RAB9AHTR5AHTR1A | |
| SCHEMBL5786283 | 0.75 | NPC1 (0.44) | LMNAKMT2ANPC1RAB9A | |
| SCHEMBL11107148 | 0.75 | ALDH1A1 (0.41) | KMT2ANPC1RAB9AHTR5AHTR1A | |
| SCHEMBL129925 | 0.74 | PDE4D (0.49) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | PDE4A 6/4885PDE4B 4/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.